

How does Xofluza work? Learn how this single-dose flu medication stops the influenza virus, how fast it acts, and what makes it different from Tamiflu.
Xofluza (baloxavir marboxil) works by blocking a specific enzyme the flu virus needs to copy itself, stopping the infection at its source with a single dose.
To understand how Xofluza works, it helps to know a little about how the flu virus operates inside your body.
When an influenza virus infects one of your cells, it essentially hijacks your cell's machinery to make copies of itself. The virus needs to create copies of its genetic material (RNA) to spread. To do this, it relies on a specific enzyme called cap-dependent endonuclease — part of the virus's own replication system.
Think of it like a photocopier. The virus needs this enzyme to start the copying process. Xofluza works by jamming that photocopier. It blocks the endonuclease enzyme, which means the virus can't copy its genetic material. No copies, no new virus particles. The infection stalls.
This is fundamentally different from how older flu drugs work, which is why Xofluza is classified as a cap-dependent endonuclease inhibitor — it's the first and only medication in this class approved for flu treatment.
Here's the step-by-step process:
The result: the flu runs a shorter, milder course than it would without treatment.
Clinical trials showed that Xofluza significantly reduced the duration of flu symptoms compared to placebo. Patients who took Xofluza experienced relief of symptoms roughly one day sooner than those who didn't receive treatment.
At the cellular level, Xofluza starts working quickly. Studies showed a significant reduction in viral load (the amount of virus in your body) within 24 hours of taking the dose — faster than Tamiflu in head-to-head comparisons.
However, it's important to set realistic expectations: Xofluza doesn't make the flu disappear overnight. You'll still feel sick for a few days. What it does is shorten the duration and potentially reduce the severity of your symptoms.
One of the remarkable things about Xofluza is its long half-life. The active compound, baloxavir, has a half-life of approximately 79 hours. This means a single dose stays active in your body for several days — which is why one dose is sufficient, compared to Tamiflu's five-day, twice-daily regimen.
You don't need to take any additional doses. One pill and you're done.
There are several antiviral medications used to treat the flu. Here's how Xofluza compares:
For a detailed comparison of all flu treatment options, see our guide to Xofluza alternatives.
Xofluza is effective against both influenza A and influenza B viruses. In non-clinical studies, it has also shown activity against certain avian influenza strains (like H5N1 and H7N9) and against oseltamivir-resistant strains, though these are not FDA-approved indications.
One consideration: in clinical trials, some patients developed viruses with reduced susceptibility to Xofluza (known as PA/I38T variant). This was more common in children and typically did not affect clinical outcomes in otherwise healthy patients, but it's something researchers continue to monitor.
Xofluza 80 Mg Dose Pack works by targeting the flu virus's replication machinery — specifically, the cap-dependent endonuclease enzyme that the virus needs to copy itself. This first-in-class mechanism allows it to work with just a single dose, reducing viral load faster than older neuraminidase inhibitors like Tamiflu.
If you'd like to learn more about Xofluza, check out our guides on uses and dosage, side effects, and drug interactions. Ready to fill your prescription? Use Medfinder to find a pharmacy with Xofluza in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.